NEW YORK, NY / ACCESSWIRE / November 7, 2017 / It was a good start to the week for Teva Pharmaceutical on Monday, as a Reuters report revealed that a British billionaire may be interested in a $3 billion stake in the company. Shares had been clobbered last week after missing on earnings and even received a price target slash from Credit Suisse yesterday. TherapeuticsMD saw big gains yesterday as well after a positive announcement about the FDA allowing for the resubmission of the company's TX-004 New Drug Application, without the need for another pre-approval study.

RDI Initiates Coverage on:

Teva Pharmaceutical Industries Limited
http://www.rdinvesting.com/report/?ticker=TEVA

TherapeuticsMD, Inc.
http://www.rdinvesting.com/report/?ticker=TXMD

Teva Pharmaceutical Industries Limited shares closed up 8.86% on Monday after news revealed that a British billionaire may be interested in buying a stake in the company. Traders were excited over the report and Teva saw its trading volume climb to nearly 61 million shares. The Israeli drug maker just released third-quarter earnings that missed as well as slashed 2017 guidance last week. Wall Street learning about the Reuters report that Len Blavatnik may be wanting to acquire up to a $3 billion stake in the company renewed some trader optimism yesterday. Shares of Teva were at a 17-year low last week. Credit Suisse analyst Vamil Divan also cut his price target on the stock from $14 to $8 and said, "Teva left a lot of questions unanswered on their conference call. This is understandable since the new CEO just joined the company the day before, but the lack of insight is still frustrating."

Access RDI's Teva Pharmaceutical Industries Limited Research Report at:
http://www.rdinvesting.com/report/?ticker=TEVA

TherapeuticsMD, Inc. shares were on fire in yesterday's trading session, closing the day up 31.65% on significant volume traded. The stock traded nearly 32 million shares compared to an average of just around 2.5 million shares. So why the big move? It seems a positive FDA resolution had investors cheering. The company announced on Monday that the FDA has agreed to the resubmission of its TX-004 New Drug Application (NDA) for vulvar vaginal atrophy (VVA), without the need for an additional pre-approval study. William Tanner, an analyst at Cantor remarked, "Based on the recent meeting with the FDA, we believe TX-004 is clearly on the path to approval and believe it will be an important new treatment for vulvar vaginal atrophy (VVA). We believe investor confidence in the viability of the entire enterprise, not just the asset, should increase with today's announcement. We believe 2018 is setting up to be an important year for the company with two FDA approvals possible and the launch of a major product likely." The firm has a $32 price target on the stock with an "overweight" rating.

Access RDI's TherapeuticsMD, Inc. Research Report at:
http://www.rdinvesting.com/report/?ticker=TXMD

Our Actionable Research on Teva Pharmaceutical Industries Limited (NYSE: TEVA) and TherapeuticsMD, Inc. (NASDAQ: TXMD) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com